Archives
- 2026-07
- 2026-06
- 2026-05
- 2026-04
- 2026-03
- 2026-02
- 2026-01
- 2025-12
- 2025-11
- 2025-10
- 2025-09
- 2025-03
- 2025-02
- 2025-01
- 2024-12
- 2024-11
- 2024-10
- 2024-09
- 2024-08
- 2024-07
- 2024-06
- 2024-05
- 2024-04
- 2024-03
- 2024-02
- 2024-01
- 2023-12
- 2023-11
- 2023-10
- 2023-09
- 2023-08
- 2023-07
- 2023-06
- 2023-05
- 2023-04
- 2023-03
- 2023-02
- 2023-01
- 2022-12
- 2022-11
- 2022-10
- 2022-09
- 2022-08
- 2022-07
- 2022-06
- 2022-05
- 2022-04
- 2022-03
- 2022-02
- 2022-01
- 2021-12
- 2021-11
- 2021-10
- 2021-09
- 2021-08
- 2021-07
- 2021-06
- 2021-05
- 2021-04
- 2021-03
- 2021-02
- 2021-01
- 2020-12
- 2020-11
- 2020-10
- 2020-09
- 2020-08
- 2020-07
- 2020-06
- 2020-05
- 2020-04
- 2020-03
- 2020-02
- 2020-01
- 2019-12
- 2019-11
- 2019-10
- 2019-09
- 2019-08
- 2019-07
- 2019-06
- 2018-07
-
Neuromedin S (rat): Technical Guidance for GPCR Signaling St
2026-07-09
Neuromedin S (rat) provides a defined, endogenous agonist for selective activation of neuromedin U receptor signaling in rat-based GPCR/G protein research. It enables controlled studies on pathways such as energy homeostasis regulation and stress response. This reagent is not intended for diagnostic or therapeutic use, and should be handled under rigorous laboratory standards.
-
Brain-to-Spinal Circuits Regulate Mechanical Allodynia Later
2026-07-09
Huo et al. (2023) delineate a contralateral brain-to-spinal circuit that controls both the laterality and duration of mechanical allodynia in mice. This work provides mechanistic insight into pain asymmetry, highlighting specific hypothalamic and spinal pathways as key modulators—offering new frameworks for preclinical pain modeling.
-
TH287 MTH1 Inhibitor Enhances Radiosensitivity in CRPC Cells
2026-07-08
This study demonstrates that TH287, a potent MTH1 inhibitor, significantly sensitizes castration-resistant prostate cancer (CRPC) cells to ionizing radiation by promoting DNA damage and apoptosis. The findings provide mechanistic and protocol insights for optimizing radiosensitization timing and maximizing selective cancer cell cytotoxicity.
-
Distinguishing Viability Metrics for Cancer Drug Evaluation
2026-07-08
Schwartz's dissertation advances preclinical oncology by disentangling the effects of anti-cancer drugs on cell proliferation versus cell death, using improved in vitro metrics. This distinction clarifies drug response interpretations, particularly for apoptosis inducers such as pan-Bcl-2 inhibitors, thereby refining experimental design and efficacy assessment.
-
CCK-8s Stimulates ANP Secretion via NOX4–PGC-1α–PPAR Signali
2026-07-07
This study reveals that sulfated cholecystokinin octapeptide (CCK-8s) directly promotes atrial natriuretic peptide (ANP) secretion in isolated rat atria by activating the NOX4–PGC-1α–PPARα/γ signaling pathway. The findings clarify the molecular interface between cardiac peptide regulation, oxidative stress, and gene expression, with implications for cardiovascular inflammation and redox biology research.
-
Decoding Selective MCL-1 Inhibition: A-1210477 in Advanced C
2026-07-07
Explore how the selective MCL-1 inhibitor A-1210477 enables precise apoptosis induction in cancer cells. This article delivers unique, protocol-focused insights for mitochondrial apoptosis studies—bridging assay design and translational potential.
-
Erastin Reverses ABCB1-Mediated Docetaxel Resistance in Ovar
2026-07-06
The reference study demonstrates that erastin, a ferroptosis inducer, overcomes ABCB1-mediated resistance to docetaxel in ovarian cancer cells by inhibiting drug efflux without altering ABCB1 expression. This mechanistic insight suggests new strategies for tackling multidrug resistance in chemotherapy.
-
Baicalin Methyl Ester: Mechanistic Advances in Intestinal Ba
2026-07-06
Explore the advanced mechanisms of Baicalin methyl ester, an esterified derivative of baicalin, in modulating intestinal inflammation and barrier protection. This article delivers new depth on assay decision-making and translational value not addressed elsewhere.
-
MOG (35-55) Peptide: Optimizing Autoimmune Encephalomyelitis
2026-07-05
MOG (35-55) Peptide is the gold-standard tool for inducing reliable experimental autoimmune encephalomyelitis, enabling robust neuroinflammation and multiple sclerosis research. Learn how to streamline workflows, troubleshoot common issues, and leverage cutting-edge mechanistic insights with this benchmark myelin oligodendrocyte glycoprotein peptide.
-
Danazol as a Precision Modulator: Mechanisms, Models, and HP
2026-07-04
Explore how Danazol, a synthetic androgenic steroid, advances endocrine and prostate cancer research by targeting the HPG axis and steroidogenesis. This in-depth analysis reveals unique mechanistic insights, translational assay strategies, and critical findings not covered by typical protocol guides.
-
Indomethacin in Inflammation Research: Protocols and Pitfall
2026-07-03
Indomethacin empowers inflammation and lipid metabolism studies by combining Cox-1 selectivity with unique membrane and PPARγ modulation. This guide delivers actionable protocols, troubleshooting, and insights from cutting-edge adipocyte research to help scientists achieve robust, reproducible results.
-
FXR–KLF11 Axis Mitigates Inflammation in Contrast-Induced AK
2026-07-03
This study uncovers the FXR–KLF11 axis as a critical regulator that suppresses JAK2/STAT3-driven inflammation and apoptosis in contrast-induced acute kidney injury (CI-AKI). By elucidating how FXR activation transcriptionally upregulates KLF11 to confer nephroprotection, the findings open new avenues for targeted anti-inflammatory strategies in renal injury models.
-
1-myristoylglycerophosphocholine: Lipid Signaling Insights f
2026-07-02
Explore how 1-myristoylglycerophosphocholine advances lipid signaling pathway analysis and smooth muscle research. This in-depth review reveals new mechanistic and assay design insights, building on recent breakthroughs in fibroblast activation and pulmonary fibrosis.
-
Z-VEID-FMK: Caspase-6 Inhibitor Workflows for Apoptosis Rese
2026-07-02
Z-VEID-FMK empowers researchers to dissect caspase-6–dependent apoptosis with high specificity, driving new insights into neurodegeneration, cancer, and host-pathogen immunity. This guide delivers stepwise protocols and troubleshooting tips, translating emerging immunology findings into actionable experimental strategies.
-
AG-120 (Ivosidenib): Optimizing Mutant IDH1 AML Research Pro
2026-07-01
AG-120 (Ivosidenib) empowers researchers to achieve robust 2-hydroxyglutarate reduction and restore myeloid differentiation in IDH1-mutant AML models. This guide translates cutting-edge findings in metabolic rewiring into actionable protocols and troubleshooting strategies for reproducible, high-impact results.